If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Mcmuff. You area breath of fresh air mate
We shall see, Timster. Would be beneficial if it was non dilutional. And also begs the question about the money spent on the dx acquisitions from most recent raise. Hopefully they are profitable.
Yes Avacta 43% down since the value curve comment.
Here come the bed wetter abuse comments
Daprophet. If this is a dip I'd hate to what share price crash looks like! Yes, it's AIM but all the same Avacta need to steady the ship here
Daprophet.
No they didn't. Al said not to worry about financing and rather do non dilutive (not verbatim). Eliot forster then threw in option of equity. This was at the Science Day if I remember rightly.
This will be the most most important AACR in Avacta's history surely?
Im intrigued by whether they are obliged to release to market any sensitive news the poster contains on submission.
Heavens above, Touk
Tumours miraculously shrinking! What next? We should be worried that the Avacta BOD all get struck by lightning at the same time.
Quite risky to have an open short going by that logic?
So surely avacta will have to release the full 1a data if they are potentially submitting to AACR conference organisers on March 5th?
"The assumption is that it works wonderfully well, but at this stage it is just an assumption."
In December Avacta (CC) did a presentation singing the praises of how well the trial has gone! What on earth are you on about?
It's safe to say in any case that the poster will contain a whole hose of information about 1a and all positive judging by the december presentation.
I should imagine there will be an update for arm 2 shortly before as well.
That's a question for a nomad, thorn. Not an lse board.
His 20k twitter followers?
Dtw
The share price is also down over 30% since December 13th.
Perhaps the market is confused. Amd this feeds shorting. Feel free to abuse
Somewhat aggressive.
Its a valid question.... Another communication from the company mentioned it's starting in parallel with end of last cohort as well as needing FDA approval.
Then some poster have communicated with Avacta and heard doesnt require FDA approval and that Avacta will let the market know when the 3rd person has been dosed.
So it is a valid question as there is some confusion.
This was December 13
The next steps with AVA6000 involve optimising the patient population, dose and schedule in order to increase efficacy and tolerability of doxorubicin treatment via pre|CISION(TM) targeting. Given the favourable safety data from the three-weekly dosing study, a fortnightly dosing study, which is now screening patients with high FAP levels in the United States, will assist in optimising the schedule and dose for a potentially pivotal Phase 2 study in 2024.
Anybody know if this has actually started? Patients been dosed?
It's not going in the right direction! Come on Avacta, lets get some momentum.
Bring in a big investor at least
Touk, I don't get where you are coming from at all.
The 3 weekly dose showed remarkable safety and therefore they decided that it should be tried at 2 weekly, probably at lower dose and for longer as there are less side affects.